Alnylam Pharmaceuticals Inc (ALNY)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$397.94
Buy
$420.00
$-15.08 (-3.65%)
Prices updated at 13 Dec 2025, 00:32 EST
| Prices minimum 15 mins delay
Prices in USD
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 85.62 |
| 2023 | 83.02 |
| 2022 | 83.73 |
| 2021 | 83.40 |
| 2020 | 84.16 |
| 2019 | 88.60 |
| 2018 | 97.59 |
| 2017 | 100.00 |
| 2016 | 100.00 |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 16.46 |
| 2024 | 14.24 |
| 2023 | 13.81 |
| 2022 | 29.88 |
| 2021 | 27.04 |
| 2020 | 36.91 |
| 2019 | 72.59 |
| 2018 | 78.93 |
| 2017 | 160.94 |
| 2016 | 85.78 |
| 2015 | 134.13 |
Price/Forward earnings (YTD)
44.84
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -6.89 |
| 2023 | -11.94 |
| 2022 | -31.47 |
| 2021 | -24.19 |
| 2020 | -29.58 |
| 2019 | -44.64 |
| 2018 | -42.67 |
| 2017 | -30.14 |
| 2016 | -30.96 |
| 2015 | -23.52 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 63.20 |
| 2023 | - |
| 2022 | - |
| 2021 | 6.19 |
| 2020 | 3.35 |
| 2019 | 1.66 |
| 2018 | 1.21 |
| 2017 | 1.13 |
| 2016 | 1.37 |
| 2015 | 1.10 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
